Cardiac Dysfunction in Patients With Non-alcoholic Fatty Liver Disease

Cardiac Disease Clinical Trial

Official title: Cardiac Dysfunction in Patients With Non-alcoholic Fatty Liver Disease

Status Recruiting

Clinical Trial Summary

Cirrhotic cardiomyopathy is seen as a blunted contractile responsiveness to stress, and/or altered diastolic relaxation with electrophysiological abnormalities, in absence of known cardiac disease. Left ventricular diastolic dysfunction (LVDD) is associated with risk of hepatorenal syndrome (HRS) , septic shock. , heart failure in the perioperative period following liver transplantation, and after trans-jugular intrahepatic portosystemic shunt (TIPS) insertion . The echocardiographic E/e' ratio is a predictor of survival in LVDD, with multiple studies, including prospective data from our Centre. The inability of the heart to cope with stress or sepsis induced circulatory failure is a key concept of the increased mortality risk due to LVDD. In view of the metabolic syndrome and diabetes epidemic and an increasing number of patients being diagnosed with non-alcoholic fatty liver disease, there is increased risk of developing cardiac dysfunction due to multiple comorbidities including coronary artery disease, hypertensive heart disease, cirrhotic cardiomyopathy, which are contributors to overall cardiovascular risk of mortality.

Clinical Trial Description

Nonalcoholic fatty liver disease (NAFLD) and heart failure (HF) are obesity-related conditions with high cardiovascular mortality. Many new studies have linked NAFLD to changes in myocardial energy metabolism, and to echocardiographic measurements of cardiac dysfunction especially heart failure with preserved ejection fraction. Cardiac dysfunction in NAFLD is related to the release of inflammatory cytokines among those with steatohepatitis (NASH). However composite models looking at coronary artery disease, systolic and diastolic heart failure and outcomes in patients with NAFLD are limited, and the few preliminary analyses of this relationship using histologically-defined NASH or lean NAFLD remain unclear.

In this project the investigators will screen patients with a diagnosis of 'non-alcoholic fatty liver disease' for presence of coronary artery disease, arrhythmias, cirrhotic cardiomyopathy and develop a model for cardiac dysfunction in such patients. ;

Related Conditions & MeSH terms

• Cardiac Disease
• Fatty Liver
• Heart Diseases
• Liver Diseases
• NAFLD
• Non-alcoholic Fatty Liver Disease

• NCT number: NCT06386094
• Study type: Observational
• Source: Post Graduate Institute of Medical Education and Research, Chandigarh
• Contact: Madhumita Premkumar
• Phone: 01722754777
• Email: drmadhumitap@gmail.com
• Status: Recruiting
• Start date: July 15, 2023
• Completion date: November 15, 2025